Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1974 Nov;18(3):391–405.

Studies of serum complement in the hypocomplementaemic nephritides

D Gwyn Williams, D K Peters, Jane Fallows, Aviva Petrie, O Kourilsky, Liliane Morel-Maroger, J S Cameron
PMCID: PMC1537992  PMID: 4219908

Abstract

The sera from forty patients with mesangiocapillary glomerulonephritis (MCGN), fifty-two patients with acute glomerulonephritis (AGN) and twenty-five patients with the nephritis of systemic lupus erythematosus (SLE) were examined for concentrations of C1q, C4, C3, C5, C6, C7, glycine-rich beta glycoprotein (GBG) and properdin, for their ability to generate cobra factor-dependent convertase, and for the presence of C3 splitting activity.

Two types of C3 splitting activity were found. The first, which caused C3 breakdown in normal human serum in the presence of Mg2+–EGTA, was in MCGN and in a minority of patients with AGN. The second, which failed to break down C3 in either Mg2+–EGTA or EDTA, was found in SLE and AGN. In MCGN and AGN low values of C1q and C4 were found, and there was a significant correlation between the concentrations of these components, suggesting activation of the classical pathway. In SLE much greater reduction in C1q and C4 was observed. Significant reduction in GBG was found in each disease with a significant correlation of GBG with C4 and, in MCGN and SLE, with C3. In AGN and SLE there were significant overall reductions in properdin levels and a good correlation between C3 and properdin, whereas in MCGN, although five of the forty patients had a low properdin there was no correlation between C3 and properdin, and no overall reduction in properdin. These data suggest that complement is activated via the classical and C3b-feedback pathways in MCGN, AGN and SLE, but do not provide evidence for a role for properdin in causing hypocomplementaemia in MCGN.

The two histological variants of MCGN were found to differ in their complement concentrations; patients with intramembranous deposits had a lower C3 concentration and those with subendothelial deposits a lower C4 concentration, suggesting different pathogenetic mechanisms in these two types of MCGN.

Full text

PDF
391

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agnello V., Winchester R. J., Kunkel H. G. Precipitin reactions of the C1q component of complement with aggregated gamma-globulin and immune complexes in gel diffusion. Immunology. 1970 Dec;19(6):909–919. [PMC free article] [PubMed] [Google Scholar]
  2. Alper C. A., Rosen F. S. Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients. J Clin Invest. 1967 Dec;46(12):2021–2034. doi: 10.1172/JCI105691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Arisz L., Brentjens J. R., van der Hem G. K., Mandema E. Clinical value of serum B 1A - and B 1E -globulin levels in adult patients with renal disease. Acta Med Scand. 1972 Oct;192(4):255–261. doi: 10.1111/j.0954-6820.1972.tb04812.x. [DOI] [PubMed] [Google Scholar]
  4. BERGER J., GALLE P. D'EP OTS DENSES AU SEIN DES MEMBRANES BASALES DU REIN. ETUDE EN MICROSCOPIES OPTIQUE ET 'ELECTRONIQUE. Presse Med. 1963 Nov 20;71:2351–2354. [PubMed] [Google Scholar]
  5. BOLTAX A. J., FISCHEL E. E. Serologic tests for inflammation; serum complement, c-reactive protein and erythrocyte sedimentation rate in myocardial infarction. Am J Med. 1956 Mar;20(3):418–427. doi: 10.1016/0002-9343(56)90127-9. [DOI] [PubMed] [Google Scholar]
  6. Charlesworth J. A., Williams D. G., Sherington E., Lachmann P. J., Peters D. K. Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest. 1974 Jun;53(6):1578–1587. doi: 10.1172/JCI107708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Götze O., Müller-Eberhard H. J. The C3-activator system: an alternate pathway of complement activation. J Exp Med. 1971 Sep 1;134(3 Pt 2):90s–108s. [PubMed] [Google Scholar]
  8. Kohler P. F., Ten Bensel R. Serial complement component alterations in acute glomerulonephritis and systemic lupus erythematosus. Clin Exp Immunol. 1969 Feb;4(2):191–202. [PMC free article] [PubMed] [Google Scholar]
  9. LANGE K., GRAIG F., OBERMAN J., SLOBODY L., OGUR G., LoCASTO F. Changes in serum complement during the course and treatment of glomerulonephritis. AMA Arch Intern Med. 1951 Oct;88(4):433–445. doi: 10.1001/archinte.1951.03810100017002. [DOI] [PubMed] [Google Scholar]
  10. Levy M., Loirat C., Habib R. Idiopathic membrano-proliferative glomerulonephritis in children (corrections between light, electron, immunofluorescent microscopic appearances and serum C3 and C4 levels). Biomedicine. 1973 Oct 10;19(10):447–454. [PubMed] [Google Scholar]
  11. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  12. McLean R. H., Michael A. F. Properdin anc C3 proactivator: alternate pathway components in human glomerulonephritis. J Clin Invest. 1973 Mar;52(3):634–644. doi: 10.1172/JCI107225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Morel-Maroger L., Leathem A., Richet G. Glomerular abnormalities in nonsystemic diseases. Relationship between findings by light microscopy and immunofluorescence in 433 renal biopsy specimens. Am J Med. 1972 Aug;53(2):170–184. doi: 10.1016/0002-9343(72)90127-1. [DOI] [PubMed] [Google Scholar]
  14. PILLEMER L., BLUM L., LEPOW I. H., ROSS O. A., TODD E. W., WARDLAW A. C. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science. 1954 Aug 20;120(3112):279–285. doi: 10.1126/science.120.3112.279. [DOI] [PubMed] [Google Scholar]
  15. Peters D. K., Charlesworth J. A., Sissons J. G., Williams D. G., Boulton-Jones J. M., Evans D. J., Kourilsky O., Morel-Maroger L. Mesangiocapillary nephritis, partial lipodystrophy, and hypocomplementaemia. Lancet. 1973 Sep 8;2(7828):535–538. doi: 10.1016/s0140-6736(73)92351-9. [DOI] [PubMed] [Google Scholar]
  16. Peters D. K., Martin A., Weinstein A., Cameron J. S., Barratt T. M., Ogg C. S., Lachmann P. J. Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol. 1972 Jul;11(3):311–320. [PMC free article] [PubMed] [Google Scholar]
  17. Spitzer R. E., Vallota E. H., Forristal J., Sudora E., Stitzel A., Davis N. C., West C. D. Serum C'3 lytic system in patients with glomerulonephritis. Science. 1969 Apr 25;164(3878):436–437. doi: 10.1126/science.164.3878.436. [DOI] [PubMed] [Google Scholar]
  18. Tamura N., Nelson R. A., Jr Three naturally-occurring inhibitors of components of complement in guinea pig and rabbit serum. J Immunol. 1967 Sep;99(3):582–589. [PubMed] [Google Scholar]
  19. Vallota E. H., Forristal J., Spitzer R. E., Davis N. C., West C. D. Characteristics of a non-complement-dependent C3-reactive complex formed form factors in nephritic and normal serum. J Exp Med. 1970 Jun 1;131(6):1306–1324. doi: 10.1084/jem.131.6.1306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Williams D. G., Lachmann P. J., Charlesworth J. A., Peters D. K. Role of C3b in the breakdown of C3 in hypocomplementaemic mesangiocapillary glomerulonephritis. Lancet. 1973 Mar 3;1(7801):447–449. doi: 10.1016/s0140-6736(73)91877-1. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES